Cem Sievers
Overview
Explore the profile of Cem Sievers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fay M, Sievers C, Robbins Y, Yang X, Huynh A, Redman J, et al.
iScience
. 2024 Aug;
27(8):110520.
PMID: 39139402
A tissue resident-like phenotype in tumor infiltrating T cells can limit systemic anti-tumor immunity. Enhanced systemic anti-tumor immunity is observed in head and neck cancer patients after neoadjuvant PD-L1 immune...
2.
Norberg S, Bai K, Sievers C, Robbins Y, Friedman J, Yang X, et al.
Sci Transl Med
. 2023 Oct;
15(719):eadj0740.
PMID: 37878675
Recurrent respiratory papillomatosis (RRP) is a rare, debilitating neoplastic disorder caused by chronic infection with human papillomavirus (HPV) type 6 or 11 and characterized by growth of papillomas in the...
3.
Sakakibara N, Clavijo P, Sievers C, Gray V, King K, George A, et al.
Front Immunol
. 2023 Aug;
14:1200970.
PMID: 37638000
Introduction: Amplification of human chromosome 3q26-29, which encodes oncoprotein ΔNp63 among other isoforms of the p63 family, is a feature common to squamous cell carcinomas (SCCs) of multiple tissue origins....
4.
Nigam N, Bernard B, Sevilla S, Kim S, Dar M, Tsai D, et al.
Cell Rep
. 2023 Jul;
42(7):112823.
PMID: 37463106
Cancers often display immune escape, but the mechanisms are incompletely understood. Herein, we identify SMYD3 as a mediator of immune escape in human papilloma virus (HPV)-negative head and neck squamous...
5.
Redman J, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, et al.
J Clin Invest
. 2023 Jun;
133(11).
PMID: 37259923
No abstract available.
6.
Sievers C, Craveiro M, Friedman J, Robbins Y, Yang X, Bai K, et al.
Cancer Cell
. 2023 Apr;
41(5):887-902.e5.
PMID: 37059104
Neoadjuvant immunotherapies (NITs) have led to clinical benefits in several cancers. Characterization of the molecular mechanisms underlying responses to NIT may lead to improved treatment strategies. Here we show that...
7.
Robbins Y, Friedman J, Redman J, Sievers C, Lassoued W, Gulley J, et al.
Oral Oncol
. 2023 Jan;
138:106309.
PMID: 36682187
Objectives: Biomarkers are needed to identify patients likely to respond to neoadjuvant immunotherapy (NIT) prior to receiving definitive treatment. Materials And Methods: We hypothesized that expression of tumor cell HLA...
8.
Bai K, Norberg S, Sievers C, Meyer T, Friedman J, Hinrichs C, et al.
Head Neck
. 2022 Jul;
44(10):E31-E37.
PMID: 35815785
Background: Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, we report durable disease control over many years following PD-L1 blockade through induction of a viral...
9.
Redman J, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, et al.
J Clin Invest
. 2022 Jun;
132(18).
PMID: 35727629
BACKGROUNDHead and neck squamous cell carcinoma not associated with HPV (HPV-unrelated HNSCC) is associated with a high rate of recurrence and poor survival.METHODSWe conducted a clinical trial in 14 patients...
10.
Hong Y, Robbins Y, Yang X, Mydlarz W, Sowers A, Mitchell J, et al.
JCI Insight
. 2022 Mar;
7(5).
PMID: 35260537
Therapeutic IL-12 has demonstrated the ability to reduce local immune suppression in preclinical models, but clinical development has been limited by severe inflammation-related adverse events with systemic administration. Here, we...